opc 4392 has been researched along with aripiprazole in 6 studies
Studies (opc 4392) | Trials (opc 4392) | Recent Studies (post-2010) (opc 4392) | Studies (aripiprazole) | Trials (aripiprazole) | Recent Studies (post-2010) (aripiprazole) |
---|---|---|---|---|---|
16 | 1 | 0 | 2,989 | 509 | 1,788 |
Protein | Taxonomy | opc 4392 (IC50) | aripiprazole (IC50) |
---|---|---|---|
ATP-dependent translocase ABCB1 | Homo sapiens (human) | 0.78 | |
D(2) dopamine receptor | Homo sapiens (human) | 0.0158 | |
5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.945 | |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 1.38 | |
Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.17 | |
Histamine H1 receptor | Homo sapiens (human) | 0.42 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.8572 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (50.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kikuchi, T; Kurahashi, N; Nishi, T; Oshiro, Y; Sato, S; Tanaka, T; Tottori, K; Uwahodo, Y | 1 |
Gonzalez, AM; Jiang, D; Lawler, CP; Lewis, MM; Mailman, RB; Mak, C; Prioleau, C; Schetz, JA; Sibley, DR | 1 |
Fujikawa, M; Furukawa, T; Inoue, T; Nagashima, M; Yamada, K | 1 |
Burris, KD; Kikuchi, T; Miwa, T; Mori, T; Stark, A; Tadori, Y; Tottori, K | 1 |
Chen, R; Johnson, JL; Jordan, S; Kambayashi, J; Kikuchi, T; Kitagawa, H; McQuade, R; Regardie, K; Tadori, Y | 1 |
Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y | 1 |
6 other study(ies) available for opc 4392 and aripiprazole
Article | Year |
---|---|
Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
Topics: 4-Butyrolactone; Animals; Antipsychotic Agents; Apomorphine; Aripiprazole; Brain; Catalepsy; Dihydroxyphenylalanine; Dopamine Agonists; Dopamine Antagonists; GABA Modulators; Male; Mice; Mice, Inbred ICR; Molecular Structure; Piperazines; Quinolones; Rats; Stereotyped Behavior; Structure-Activity Relationship | 1998 |
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
Topics: Animals; Antipsychotic Agents; Aripiprazole; CHO Cells; Corpus Striatum; Cricetinae; Glioma; Piperazines; Quinolones; Rats; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Tumor Cells, Cultured | 1999 |
Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Azepines; Dopamine Agonists; Drug Synergism; Male; Oxidopamine; Piperazines; Piperidines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine; Stereotyped Behavior; Sympathectomy, Chemical; Yawning | 1996 |
Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Binding, Competitive; Cell Membrane; CHO Cells; Colforsin; Cricetinae; Cricetulus; Cyclic AMP; DNA, Complementary; Dopamine; Dopamine Agonists; Dopamine Antagonists; Haloperidol; Humans; Lisuride; Piperazines; Piperidines; Quinolones; Raclopride; Radioligand Assay; Receptors, Dopamine D2; Risperidone; Transfection; Tritium | 2005 |
In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Calcium Signaling; CHO Cells; Cloning, Molecular; Cricetinae; Cricetulus; Dopamine; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Immunoblotting; Lisuride; MAP Kinase Signaling System; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Phosphorylation; Piperazines; Piperidines; Quinolones; Raclopride; Receptors, Dopamine D2; Schizophrenia; Time Factors; Transfection | 2007 |
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia | 2007 |